NCT02836028View on ClinicalTrials.gov

A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2016

Primary Completion Date

June 30, 2020

Conditions
Ovarian Cancer
Interventions
DRUG

Talazoparib

Talazoparib monotherapy 1mg/day orally

DRUG

Temozolomide

temozolomide 37.5 mg/m2 on days 1-5 of each cycle

Sponsors

Lead Sponsor

Pfizer

Collaborators (1)

Medivation, Inc.
All Listed Sponsors
collaborator

Myriad Genetic Laboratories, Inc.

INDUSTRY

collaborator

Medivation, Inc.

INDUSTRY

lead

Pfizer

INDUSTRY

NCT02836028 - A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer | Biotech Hunter | Biotech Hunter